MedPath

Sonar Guided vs Surgeon Delivered Parasternal Block

Not Applicable
Not yet recruiting
Conditions
Parasternal Intercostal Nerve Block
Interventions
Procedure: US-guided Parasternal block
Procedure: Surgeon-delivered parasternal block
Registration Number
NCT05518266
Lead Sponsor
Assiut University
Brief Summary

The objective of this study is to determine whether the use of post-incisional surgeon-delivered parasternal block is at least non-inferior in relieving postoperative pain in adult patients scheduled for cardiac surgery involving sternotomy compared with ultrasound-guided post-incisional PIFB.

Detailed Description

Patients will be randomly allocated (using a sequence of computer-generated random numbers) into one of two groups (44 patients in each); group P (ultrasound guided parasternal; PIFP block) and group S (surgeon delivered parasternal block).

1. group P (ultrasound guided parasternal; PIFP block): Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance

2. Group S (surgeon delivered parasternal block). Just before wiring the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
88
Inclusion Criteria
  • Age: from 18 to 75 years.
  • Rheumatic heart disease needing elective valve replacement (mitral, aortic, or double valve replacement) via median sternotomy and under CPB (cardiopulmonary bypass)
  • Hemodynamic stability (no evidence of heart failure, not on vasoactive drugs, and not on mechanical ventilation).
Exclusion Criteria
  • • Previous, urgent, or emergent cardiac surgery.

    • Patients undergoing coronary artery bypass grafting (CABG)
    • local infection of the skin at the site of needle puncture,
    • Allergy to bupivacaine,
    • Coagulation disorders,
    • Clinically significant liver or kidney disease,
    • Heart failure or severe pulmonary hypertension.
    • severe renal, pulmonary, liver, or endocrine systemic disease,

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
US-guided post-incisional PIFBUS-guided Parasternal blockBupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of the sternum after skin closure under ultrasound guidance
Surgeon-delivered post-incisional parasternal blockSurgeon-delivered parasternal blockJust before wiring the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
Primary Outcome Measures
NameTimeMethod
Change in postoperative pain score24 hours

Postoperative pain score will be measured after extubation at 0, 3, 6, 12, 16, 20, and 24 hours, using a visual analog scale (VAS). We are interested in the time at which postoperative pain is most severe.

The pain VAS is a unidimensional measure of pain intensity, which has been widely used in diverse adult populations, The pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually, 10centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme.

A score of 0 is "no pain and a score of 10 is "worst imaginable pain"

Secondary Outcome Measures
NameTimeMethod
Amount of rescue analgesia24 hours

Amount of rescue analgesia (total dose of fentanyl) during the first 24 hours after extubation.

© Copyright 2025. All Rights Reserved by MedPath